Healthcare provider profile · identity verified

Abigail Krin Elliott, MD

Family Practice · WACONIA, MN · NPI 1295180586

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	452	113
Rosuvastatin Calcium	Rosuvastatin Calcium	427	115
Levothyroxine Sodium	Levothyroxine Sodium	419	96
Lisinopril	Lisinopril	391	102
Hydrochlorothiazide	Hydrochlorothiazide	386	99
Losartan Potassium	Losartan Potassium	358	96
Amlodipine Besylate	Amlodipine Besylate	322	83
Simvastatin	Simvastatin	278	76
Metoprolol Succinate	Metoprolol Succinate	233	56
Omeprazole	Omeprazole	227	62
Sertraline Hcl	Sertraline Hcl	175	39
Metoprolol Tartrate	Metoprolol Tartrate	167	33
Furosemide	Furosemide	146	43
Trazodone Hcl	Trazodone Hcl	138	35
Gabapentin	Gabapentin	135	30
Pantoprazole Sodium	Pantoprazole Sodium	132	43
Citalopram Hbr	Citalopram Hydrobromide	128	28
Metformin Hcl	Metformin Hcl	128	35
Atenolol	Atenolol	125	33
Eliquis	Apixaban	113	28
Montelukast Sodium	Montelukast Sodium	99	23
Potassium Chloride	Potassium Chloride	98	18
Alendronate Sodium	Alendronate Sodium	92	26
Prednisone	Prednisone	92	43
Escitalopram Oxalate	Escitalopram Oxalate	87	27
Metformin Hcl Er	Metformin Hcl	87	26
Tamsulosin Hcl	Tamsulosin Hcl	78	24
Famotidine	Famotidine	77	24
Warfarin Sodium	Warfarin Sodium	77	24
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	73	17
Xarelto	Rivaroxaban	72	11
Zolpidem Tartrate	Zolpidem Tartrate	70	13
Albuterol Sulfate Hfa	Albuterol Sulfate	69	34
Allopurinol	Allopurinol	68	19
Fluticasone Propionate	Fluticasone Propionate	65	23
Pravastatin Sodium	Pravastatin Sodium	65	17
Carvedilol	Carvedilol	64	18
Oxybutynin Chloride Er	Oxybutynin Chloride	57	14
Jantoven	Warfarin Sodium	56	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	55	15
Ozempic	Semaglutide	55	suppressed
Donepezil Hcl	Donepezil Hcl	53	suppressed
Duloxetine Hcl	Duloxetine Hcl	53	15
Glipizide Er	Glipizide	53	15
Clopidogrel	Clopidogrel Bisulfate	48	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	12
Torsemide	Torsemide	42	suppressed
Amoxicillin	Amoxicillin	41	21
Alprazolam	Alprazolam	39	suppressed
Buspirone Hcl	Buspirone Hcl	38	12
Cefadroxil	Cefadroxil	37	34
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	12
Lovastatin	Lovastatin	36	suppressed
Valsartan	Valsartan	36	suppressed
Dilt-Xr	Diltiazem Hcl	34	suppressed
Spironolactone	Spironolactone	33	suppressed
Valacyclovir	Valacyclovir Hcl	33	14
Celecoxib	Celecoxib	32	suppressed
Bupropion Xl	Bupropion Hcl	31	suppressed
Gemfibrozil	Gemfibrozil	31	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	31	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	17
Incruse Ellipta	Umeclidinium Bromide	28	suppressed
Lorazepam	Lorazepam	28	12
Januvia	Sitagliptin Phosphate	26	suppressed
Ventolin Hfa	Albuterol Sulfate	26	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	17
Farxiga	Dapagliflozin Propanediol	23	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	14
Trulicity	Dulaglutide	23	suppressed
Glipizide	Glipizide	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	19
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Azithromycin	Azithromycin	19	18
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Nicotrol Ns	Nicotine	18	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	17	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	17	suppressed
Cefuroxime	Cefuroxime Axetil	17	14
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Nabumetone	Nabumetone	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Desmopressin Acetate	Desmopressin Acetate	16	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	16	suppressed
Primidone	Primidone	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Estradiol	Estradiol	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Cephalexin	Cephalexin	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	12
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Topiramate	Topiramate	14	suppressed
Bydureon Bcise	Exenatide Microspheres	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	12	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error